Douglas Bootle

1.6k citations

17 papers · 1.2k indexed · 1 hit paper · h-index 13

Impact in

Oncology top 5%
- Drug Transport and Resistance Mechanisms
- Cancer-related Molecular Pathways
Genetics top 5%
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Oncology 10
- Cancer Treatment and Pharmacology 6
- Lung Cancer Research Studies 2
Pulmonary and Respiratory Medicine 8
- Advanced Breast Cancer Therapies 7

Co-authors: Prakash Mistry (3 shared papers)Wendy Dangerfield (3 shared papers)Alistair Stewart (3 shared papers)Peter Charlton (3 shared papers)Cornelia Quadt (10 shared papers)Dejan Juric (9 shared papers)Chris Liddle (2 shared papers)Mark R. Middleton (6 shared papers)
Journals: Cancer Research (4 papers)Journal of Clinical Oncology (3 papers)Anti-Cancer Drugs (2 papers)Clinical Cancer Research (1 paper)British Journal of Cancer (1 paper)
Partner nations: Switzerland United States United Kingdom

In The Last Decade

Douglas Bootle

17 papers receiving 1.2k citations

Hit Papers

align trajectories log scale

Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study 2018 · 302 citations

Peers

Countries citing papers authored by Douglas Bootle

Since Specialization

Citations

This map shows the geographic impact of Douglas Bootle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Bootle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Bootle more than expected).

Fields of papers citing papers by Douglas Bootle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Bootle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Bootle. The network helps show where Douglas Bootle may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas Bootle, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas Bootle Line = papers co-authored together Douglas Bootle links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study Journal of Clinical Oncology ·Dejan Juric, Jordi Rodón, Josep Tabernero, Filip Jankú, Howard A. Burris, Jan H.M. Schellens, Mark R. Middleton, Jordan Berlin, Martin Schüler, Marta Gil-Martín, Hope S. Rugo, Ruth Seggewiss‐Bernhardt, Alan Huang, Douglas Bootle, David Demanse, Lars Blumenstein, Christina Coughlin, Cornelia Quadt, José Baselga Hit paper breakdown →	2018	302
2	In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. PubMed ·Prakash Mistry, Alistair Stewart, Wendy Dangerfield, Sade Okiji, Chris Liddle, Douglas Bootle, Jane A. Plumb, David J. Templeton, Peter Charlton	2001	302
3	Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer JAMA Oncology ·Dejan Juric, Filip Jankú, Jordi Rodón, Howard A. Burris, Ingrid A. Mayer, Martin Schüler, Ruth Seggewiss‐Bernhardt, Marta Gil-Martín, Mark R. Middleton, José Baselga, Douglas Bootle, David Demanse, Lars Blumenstein, Karl Schumacher, Alan Huang, Cornelia Quadt, Hope S. Rugo	2018	186
4	Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours British Journal of Cancer ·M. Campone, Vincent Lévy, Emmanuelle Bourbouloux, Dominique Berton Rigaud, Douglas Bootle, Catherine Dutreix, Uwe Zoellner, N. Shand, Fabien Calvo, Éric Raymond	2009	74
5	In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II Anti-Cancer Drugs ·Prakash Mistry, Alistair Stewart, Wendy Dangerfield, Mark Baker, Chris Liddle, Douglas Bootle, Barbara Kofler, Deanne Laurie, William A. Denny, Bruce C. Baguley, Peter Charlton	2002	50
6	Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Cancer Research ·Dejan Juric, Jordi Rodón, Ana M. González-Angulo, Howard A. Burris, Johanna C. Bendell, Jordan Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, José Baselga	2012	48
7	Antitumor activity of XR5944, a novel and potent topoisomerase poison Anti-Cancer Drugs ·Alistair Stewart, Prakash Mistry, Wendy Dangerfield, Douglas Bootle, Mark Baker, Barbara Kofler, Sade Okiji, Bruce C. Baguley, William A. Denny, Peter Charlton	2001	44
8	Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study. Journal of Clinical Oncology ·Ana M. González-Angulo, Dejan Juric, Guillem Argilés, Jan H.M. Schellens, Howard A. Burris, Jordan Berlin, Mark R. Middleton, Martin Schüler, Robin M.J.M. van Geel, Thorunn Helgason, Douglas Bootle, Markus Boehm, Timothy Goggin, David Demanse, Cornelia Quadt, José Baselga	2013	43
9	BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study Cancer Research ·Dejan Juric, Jordi Rodón, AM Gonzalez-Angulo, Howard A. Burris, J.C. Bendell, J. Berlin, Mark R. Middleton, Douglas Bootle, Markus Boehm, Antonin Schmitt, Nicolas Rouyrre, Cornelia Quadt, J Baseiga	2012	29
10	Population pharmacokinetics and pharmacodynamics ofBYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies British Journal of Clinical Pharmacology ·Stefan S. De Buck, Annamária Jakab, Markus Boehm, Douglas Bootle, Dejan Juric, Cornelia Quadt, Timothy Goggin	2014	25
11	Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC) Journal of Clinical Oncology ·Evelyne Lerut, Tania Roskams, Emery Goossens, Douglas Bootle, Saša Dimitrijević, Michael Stumm, N. Shand, Hendrik Van Poppel	2005	17
12	Phase I and Pharmacokinetic Study of the Polyamine Synthesis Inhibitor SAM486A in Combination with 5-Fluorouracil/ Leucovorin in Metastatic Colorectal Cancer Clinical Cancer Research ·Lia van Zuylen, John Bridgewater, Alex Sparreboom, Ferry A.L.M. Eskens, Peter de Bruijn, I. Sklenar, André Planting, Les Choi, Douglas Bootle, Christian Mueller, Jonathan A. Ledermann, Jaap Verweij	2004	16
13	Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study Cancer Research ·Dejan Juric, AM Gonzalez-Angulo, HA Burris, Martin Schüler, J.H.M. Schellens, Jordan Berlin, Avinash Gupta, Ruth Seggewiss‐Bernhardt, Bárbara Adamo, Marta Gil-Martín, Douglas Bootle, Markus Boehm, Stefan Buck, David Demanse, Cornelia Quadt, José Baselga	2013	12
14	Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer Cancer Research ·Filip Jankú, Dejan Juric, Javier Cortés, Hope S. Rugo, Howard A. Burris, Martin Schüler, Barbara Deschler-Baier, Mark R. Middleton, Marta Gil-Martín, Jordan Berlin, Eric P. Winer, Douglas Bootle, Lars Blumenstein, David Demanse, Christina Coughlin, Cornelia Quadt, José Baselga	2015	12
15	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	2023	10
16	Phase I Study of the Pi3K&Agr; Inhibitor Byl719, As a Single Agent in Patients with Advanced Solid Tumors (Ast) Annals of Oncology ·Dejan Juric, H. Burris, Martin Schüler, J. Schellens, Jordan Berlin, (unknown), Marta Gil-Martín, Arnav Gupta, Jordi Rodón, Josep Tabernero, Filip Jankú, Hope S. Rugo, Douglas Bootle, Cornelia Quadt, C. Coughlin, David Demanse, Lars Blumenstein, José Baselga	2014	7
17	359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors European Journal of Cancer Supplements ·M. Campone, Vincent Lévy, Valérie Delecroix, Emmanuelle Bourbouloux, Douglas Bootle, Chihei Tanaka, N. Shand, Felipe A. Calvo, Éric Raymond	2004	1

About Douglas Bootle

Douglas Bootle is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Genetics and Hematology, having authored 17 papers that have together received 1.2k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (11 papers), Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (6 papers), Cancer therapeutics and mechanisms (3 papers), Chronic Lymphocytic Leukemia Research (2 papers), Multiple Myeloma Research and Treatments (2 papers), Lung Cancer Research Studies (2 papers) and Neuroblastoma Research and Treatments (1 paper). The work is most often cited by research in Oncology (582 citations), Genetics (171 citations), Molecular Biology (718 citations), Cancer Research (150 citations) and Toxicology (33 citations). Douglas Bootle has collaborated with scholars based in Switzerland, United States and United Kingdom. Frequent co-authors include Prakash Mistry, Wendy Dangerfield, Alistair Stewart, Peter Charlton, Cornelia Quadt, Dejan Juric, Chris Liddle, Mark R. Middleton, Howard A. Burris and Jane A. Plumb. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Anti-Cancer Drugs, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact